Clinical trial
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients…
NCT00082433 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00082433 |
|---|---|
| Title | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer |
| Official title | A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer, Breast Cancer |
| Intervention type | Drug |
| Interventions | Ixabepilone + Capecitabine, Capecitabine |
| Enrollment | 1,221 |
| Start date | Nov 1, 2003 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | May 11, 2004 |
| Last update posted | Nov 2, 2020 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Croatia, Czechia, Denmark, France and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: